FDA ap­provals, Revlim­id LOE and Op­di­vo's la­bel ex­pan­sion head­line Bris­tol My­er­s' start to 2022

The Q1 num­bers are in from Bris­tol My­ers Squibb, set­ting the tone for the year as the phar­ma gi­ant lines up some key new drug ap­provals as a Revlim­id copy­cat bites hard­er than ex­pect­ed.

Fri­day’s re­sults showed the first num­bers since Bris­tol My­ers’ megablock­buster Revlim­id saw its first gener­ic com­pe­ti­tion make its de­but in both Eu­rope and the US. Bris­tol My­ers’ top brass Gio­van­ni Caforio told in­vestors and an­a­lysts on Fri­day’s Q1 call, “US en­try ex­pec­ta­tions re­main the same, while ex-US ero­sion is ex­pect­ed to be faster than pre­vi­ous­ly an­tic­i­pat­ed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER